切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2026, Vol. 20 ›› Issue (06) : 433 -444. doi: 10.3877/cma.j.issn.1674-0785.2026.06.004

临床研究

高密度脂蛋白相关外周血炎症指标在胆石病风险评估中的作用
姚培杰1,2, 张宗明1,2,†(), 刘立民1,2, 赵月1,2, 郭震天1,2, 张翀1,2   
  1. 1 100073 北京,国家电网公司北京电力医院普外科
    2 100073 北京,中国通用技术集团肝胆疾病临床医学研究中心(筹)
  • 收稿日期:2026-04-20 出版日期:2026-06-30
  • 通信作者: 张宗明
  • 基金资助:
    北京市科技重大专项生物医药与生命科学创新培育研究(Z171100000417056); 国中康健集团科技项目(GZKJ-KJXX-QTHT-20230626,20240429)

High-density lipoprotein-related peripheral blood inflammatory markers for risk assessment of gallstone disease

Peijie Yao1,2, Zongming Zhang1,2,†(), Limin Liu1,2, Yue Zhao1,2, Zhentian Guo1,2, Chong Zhang1,2   

  1. 1 Department of General Surgery, Beijing Electric Power Hospital, State Grid Corporation of China, Capital Medical University, Beijing 100073, China
    2 Clinical Medical Research Center for Hepatobiliary Diseases (in Preparation), China General Technology Group, Beijing 100073, China
  • Received:2026-04-20 Published:2026-06-30
  • Corresponding author: Zongming Zhang
引用本文:

姚培杰, 张宗明, 刘立民, 赵月, 郭震天, 张翀. 高密度脂蛋白相关外周血炎症指标在胆石病风险评估中的作用[J/OL]. 中华临床医师杂志(电子版), 2026, 20(06): 433-444.

Peijie Yao, Zongming Zhang, Limin Liu, Yue Zhao, Zhentian Guo, Chong Zhang. High-density lipoprotein-related peripheral blood inflammatory markers for risk assessment of gallstone disease[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2026, 20(06): 433-444.

目的

胆石病(GSD)是一种与脂质代谢紊乱及炎症反应密切相关的常见、多发病。高密度脂蛋白胆固醇(HDL-C)因其具有逆向转运胆固醇及抗炎、抗氧化的双重功能,被认为是GSD发病风险的保护因素。本研究旨在探讨三种外周血细胞(淋巴细胞、单核细胞和中性粒细胞)与HDL-C比值与GSD患病的相关性及其辅助筛查价值。

方法

基于2017年1月至2020年3月及2021年8月至2023年8月美国国家健康与营养检查调查(NHANES)计划的数据,纳入资料完整的≥20岁参与者。采用加权多因素Logistic回归模型、平滑曲线拟合(SCF)、限制性立方样条(RCS)和阈值效应分析评估淋巴细胞与HDL-C比值(LHR)、单核细胞与HDL-C比值(MHR)和中性粒细胞与HDL-C比值(NHR)与GSD的关系,并进行亚组分析和交互作用检验。进一步采用受试者工作特征曲线(ROC)分析和DeLong检验评价并比较三项指标对GSD患病的辅助识别能力。

结果

共纳入13 349名参与者,其中GSD患者1 441例(10.79%)。在调整混杂因素后,多因素Logistic回归分析显示,log2转换后的LHR、MHR和NHR均与GSD患病呈正相关,OR值分别为1.34、1.36和1.38,四分位数分组分析结果一致。SCF和RCS分析提示,LHR、MHR和NHR与GSD患病之间均呈非线性关系,并存在相应拐点。亚组分析及交互作用检验结果基本一致。ROC曲线分析显示,三项指标单独区分GSD与非GSD人群的能力有限,其中NHR的AUC相对较高,但仍需结合其他临床信息进行综合评估。

结论

LHR、MHR和NHR均与GSD患病呈正相关,可作为反映炎症反应与脂质代谢异常的潜在复合参考指标,为GSD辅助筛查和临床评估提供一定依据。

Objective

Cholelithiasis (Gallstone disease, GSD) is a common condition closely associated with lipid metabolism disorders and inflammatory responses. High-density lipoprotein cholesterol (HDL-C) may be associated with GSD through its dual functions of reverse cholesterol transport as well as anti-inflammatory and antioxidant activities. This study aimed to investigate the associations of three peripheral blood cell-to-HDL-C ratios [lymphocyte-to-HDL-C ratio (LHR), monocyte-to-HDL-C ratio (MHR), and neutrophil-to-HDL-C ratio (NHR)] with GSD, and to evaluate their potential auxiliary screening value.

Methods

Data were extracted from the National Health and Nutrition Examination Survey (NHANES) for two periods: January 2017 to March 2020 and August 2021 to August 2023. Participants aged ≥ 20 years with complete data were included. The relationships of LHR, MHR, and NHR with GSD were evaluated using weighted multivariable logistic regression models, threshold effect analyses, restricted cubic splines (RCS), and smoothed curve fitting (SCF). Subgroup analyses and interaction tests were also performed. Receiver operating characteristic (ROC) curve analysis and the DeLong test were used to evaluate and compare the discriminatory ability of the three indicators for GSD.

Results

A total of 13,349 participants were included, of whom 1,441 had GSD (10.79%). In the fully adjusted multivariable logistic regression model, each unit increase in log2-transformed LHR, MHR, and NHR was significantly associated with higher odds of GSD, with odds ratios of 1.34, 1.36, and 1.38, respectively. Quartile analyses yielded consistent results. Nonlinear associations were observed between all three ratios and GSD, with corresponding inflection points identified. Subgroup and interaction analyses demonstrated generally consistent findings across strata. ROC curve analysis showed that each of the three indicators alone had limited ability to distinguish individuals with GSD from those without, with NHR showing a relatively higher area under the curve, though its utility should be interpreted in conjunction with other clinical information.

Conclusion

LHR, MHR, and NHR were each positively associated with GSD and may serve as potential composite reference indicators reflecting inflammation and lipid metabolism. These findings provide supportive evidence for the auxiliary screening and clinical assessment of GSD.

图1 数据筛选流程图 注:NHANES为美国国家健康与营养检查调查;HDL-C为高密度脂蛋白胆固醇
表1 研究人群的加权基线特征
基线资料 总计(n=13349) 非GSD组(n=11908) GSD组(n=1441) P值
年龄(岁)a 48.00(33.00~62.00) 47.00(33.00~61.00) 59.00(46.00~70.00) <0.0001
性别[例(%)] <0.0001
女性 7061(51.60) 6025(49.11) 1036(73.41)
男性 6288(48.40) 5883(50.89) 405(26.59)
种族[例(%)] <0.0001
墨西哥裔美国人 1317(7.98) 1167(8.03) 150(7.56)
非西班牙裔黑人 2635(10.59) 2421(11.00) 214(7.02)
非西班牙裔白人 6045(62.38) 5298(61.69) 747(68.45)
其他 3352(19.05) 3022(19.29) 330(16.97)
婚姻状态[例(%)] 0.8467
是 7603(61.98) 6783(61.95) 820(62.30)
否 5746(38.02) 5125(38.05) 621(37.70)
教育水平[例(%)] 0.0777
高中以下 2146(10.53) 1904(10.42) 242(11.50)
高中 3022(26.44) 2679(26.11) 343(29.27)
高中以上 8181(63.03) 7325(63.47) 856(59.23)
PIR[例(%)] 0.9458
<1 1985(11.04) 1772(11.03) 213(11.12)
≥1 11 364(88.96) 10 136(88.97) 1228(88.88)
吸烟[例(%)] 0.0001
现在吸烟 2202(15.72) 1982(15.84) 220(14.67)
以前吸烟 3331(25.04) 2893(24.33) 438(31.30)
从不吸烟 7816(59.24) 7033(59.83) 783(54.03)
饮酒[例(%)] <0.0001
是 8863(71.76) 8019(72.96) 844(61.28)
否 2234(13.79) 1894(12.67) 340(23.61)
不清楚 2252(14.45) 1995(14.37) 257(15.11)
糖尿病[例(%)] <0.0001
是 2697(15.66) 2226(14.27) 471(27.81)
否 10 652(84.34) 9682(85.73) 970(72.19)
高血压[例(%)] <0.0001
是 6011(38.41) 5149(36.29) 862(57.09)
否 7338(61.59) 6759(63.71) 579(42.91)
高脂血症[例(%)] <0.0001
是 9272(67.33) 8146(66.07) 1126(78.45)
否 4077(32.67) 3762(33.93) 315(21.55)
BMI(kg/m2)a 28.50(24.70~33.50) 28.20(24.50~33.00) 31.60(27.10~38.70) <0.0001
淋巴细胞计数(103 cells/μL)a 2.00(1.60~2.50) 2.00(1.60~2.50) 2.10(1.70~2.50) 0.0176
单核细胞计数(103 cells/μL)a 0.50(0.40~0.70) 0.50(0.40~0.70) 0.50(0.50~0.70) 0.0228
中性粒细胞计数(103 cells/μL)a 4.00(3.10~5.10) 3.90(3.10~5.00) 4.20(3.40~5.30) 0.0596
HDL-C(mmol/L)a 1.32(1.09~1.60) 1.32(1.09~1.60) 1.32(1.11~1.55) 0.3906
LDL-C(mmol/L)a 2.79(2.22~3.41) 2.79(2.22~3.41) 2.72(2.12~3.44) 0.3081
TC(mg/dl)a 184.00(159.00~213.00) 184.00(159.00~213.00) 183.00(158.00~214.00) 0.1958
TG(mg/dl)a 94.00(65.00~139.00) 93.00(63.00~137.00) 107.00(72.00~149.00) <0.0001
LHRa 1.52(1.10~2.05) 1.51(1.10~2.05) 1.57(1.16~2.11) 0.1695
MHRa 0.40(0.30~0.55) 0.40(0.29~0.55) 0.42(0.32~0.55) 0.073
NHRa 2.97(2.11~4.12) 2.95(2.09~4.08) 3.23(2.36~4.44) 0.0001
膳食炎症指数a 1.19(-0.47~2.56) 1.15(-0.52~2.51) 1.73(0.13~2.91) <0.0001
膳食纤维摄入量(g/d)a 14.75(10.15~20.50) 14.90(10.25~20.75) 13.60(9.35~18.40) <0.0001
表2 LHR、MHR、NHR与GSD患病之间的关系
变量 模型1 模型2 模型3
OR(95%CI) P值 OR(95%CI) P值 OR(95%CI) P值
Log2-transformed LHR 1.10(0.96~1.25) 0.167 1.47(1.29~1.59) <0.001 1.34(1.12~1.59) 0.002
LHR(quartile)
Q1 1.00(Reference) 1.00(Reference) 1.00(Reference)
Q2 1.13(0.90~1.43) 0.300 1.45(1.14~1.85) 0.003 1.39(1.15~1.67) 0.002
Q3 1.13(0.89~1.43) 0.319 1.67(1.30~2.13) <0.001 1.57(1.18~2.07) 0.003
Q4 1.21(1.00~1.53) 0.107 2.16(1.67~2.79) <0.001 1.78(1.28~2.49) 0.002
P for trend 0.207 <0.001 0.001
Log2-transformed MHR 1.15(1.02~1.29) 0.028 1.50(1.32~1.72) <0.001 1.36(1.17~1.57) <0.001
MHR(quartile)
Q1 1.00(Reference) 1.00(Reference) 1.00(Reference)
Q2 1.27(1.00~1.61) 0.049 1.50(1.18~1.91) 0.001 1.49(1.08~2.07) 0.018
Q3 1.32(1.05~1.67) 0.019 1.77(1.39~2.25) <0.001 1.63(1.29~2.06) <0.001
Q4 1.20(0.96~1.51) 0.109 1.95(1.52~2.50) <0.001 1.65(1.25~2.18) 0.001
P for trend 0.118 <0.001 <0.001
Log2-transformed NHR 1.29(1.15~1.45) <0.001 1.55(1.37~1.77) <0.001 1.38(1.19~1.60) <0.001
NHR(quartile)
Q1 1.00(Reference) 1.00(Reference) 1.00(Reference)
Q2 1.21(0.95~1.56) 0.127 1.39(1.08~1.80) 0.012 1.29(0.88~1.88) 0.175
Q3 1.38(1.09~1.75) 0.009 1.70(1.32~2.19) <0.001 1.52(1.17~1.98) 0.003
Q4 1.58(1.25~2.00) <0.001 2.23(1.73~2.87) <0.001 1.77(1.30~2.40) <0.001
P for trend <0.001 <0.001 <0.001
图2 LHR、MHR、NHR与GSD关联的平滑曲线 注:实线为平滑曲线,上下虚线之间的面积表示95%置信区间;LHR为淋巴细胞与HDL-C比值;MHR为单核细胞与HDL-C比值;NHR为中性粒细胞与HDL-C比值;GSD为胆石病
图3 LHR、MHR、NHR与GSD关联的限制性立方样条曲线 注:实线表示限制性立方样条拟合曲线,阴影带代表拟合的95%置信区间;LHR为淋巴细胞与HDL-C比值;MHR为单核细胞与HDL-C比值;NHR为中性粒细胞与HDL-C比值;GSD为胆石病
表3 LHR、MHR、NHR对GSD的阈值效应分析
表4 LHR、MHR、NHR与GSD相关性的亚组分析
亚组 LHR MHR NHR
OR(95%CI) P值 P for interaction OR(95%CI) P值 P for interaction OR(95%CI) P值 P for interaction
年龄 0.086 0.681 0.096
≥20,<50 1.23(1.04,1.45) 0.022 1.31(0.83,2.04) 0.251 1.16(1.09,1.23) <0.001
≥50 1.04(0.96,1.13) 0.290 1.45(1.06,2.00) 0.026 1.09(1.03,1.15) 0.006
性别 0.001 0.005 0.867
女性 1.29(1.15,1.45) <0.001 4.04(2.61,6.27) <0.001 1.14(1.09,1.18) <0.001
男性 0.97(0.84,1.12) 0.681 1.56(0.96,2.54) 0.083 1.14(1.05,1.24) 0.003
教育水平 0.282 0.015 0.022
高中以下 0.92(0.74,1.15) 0.471 0.62(0.28,1.35) 0.234 1.00(0.91,1.10) 0.978
高中 1.02(0.84,1.24) 0.846 1.26(0.71,2.22) 0.436 1.05(0.94,1.16) 0.384
高中以上 1.04(0.98,1.12) 0.208 1.75(1.23,2.50) 0.004 1.14(1.08,1.20) <0.001
吸烟 0.323 0.463 0.007
从不吸烟 1.09(0.97,1.23) 0.173 1.65(1.22,2.23) 0.003 1.15(1.09,1.21) <0.001
以前吸烟 1.00(0.93,1.08) 0.955 0.91(0.51,1.60) 0.743 1.05(0.96,1.14) 0.289
现在吸烟 1.17(1.02,1.35) 0.035 1.22(0.49,3.06) 0.669 1.01(0.93,1.10) 0.800
饮酒 0.301 0.142 0.788
是 1.12(0.95,1.32) 0.202 1.56(1.00,2.46) 0.06 1.05(0.96,1.15) 0.261
否 1.03(0.97,1.09) 0.335 1.23(0.83,1.84) 0.313 1.11(1.05,1.18) 0.001
不清楚 0.95(0.75,1.20) 0.658 0.69(0.26,1.87) 0.472 1.03(0.91,1.16) 0.627
高血压 0.884 0.052 0.815
是 1.03(0.96,1.11) 0.369 1.38(0.96,1.98) 0.086 1.08(1.01,1.15) 0.029
否 1.02(0.87,1.19) 0.816 0.77(0.48,1.22) 0.275 1.06(0.99,1.14) 0.085
糖尿病 0.402 0.385 0.957
是 1.01(1.00,1.02) 0.012 1.00(0.68,1.49) 0.988 1.06(1.01,1.11) 0.031
否 1.10(0.91,1.33) 0.340 1.29(0.84,1.99) 0.251 1.06(0.97,1.16) 0.225
表5 LHR、MHR、NHR对GSD患病的ROC曲线分析
图4 LHR、MHR、NHR对GSD患病的ROC曲线 注:灰色实线表示AUC=0.5的无判别能力参考线;LHR、MHR和NHR的AUC分别为0.519、0.522和0.547;LHR为淋巴细胞与HDL-C比值;MHR为单核细胞与HDL-C比值;NHR为中性粒细胞与HDL-C比值;GSD为胆石病;HDL-C为高密度脂蛋白胆固醇;ROC为受试者工作特征曲线;AUC为曲线下面积
表6 LHR、MHR和NHR的AUC差异DeLong检验结果
1
Wang X, Yu W, Jiang G, et al. Global epidemiology of gallstones in the 21st century: A systematic review and meta-analysis [J]. Clin Gastroenterol Hepatol, 2024, 22(8): 1586-1595.
2
Patel H, Jepsen J. Gallstone disease: common questions and answers [J]. Am Fam Physician, 2024, 109(6): 518-524.
3
Diehl AK. Gallstone size and the risk of gallbladder cancer [J]. JAMA, 1983, 250(17): 2323-2326.
4
Lowenfels AB, Walker AM, Althaus DP, et al. Gallstone growth, size, and risk of gallbladder cancer: an interracial study [J]. Int J Epidemiol, 1989, 18(1): 50-54.
5
Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome [J]. Clin Epidemiol, 2014, 6: 99-109.
6
Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease [J]. Lancet, 2006, 368(9531): 230-239.
7
Shaffer EA. Gallstone disease: Epidemiology of gallbladder stone disease [J]. Best Pract Res Clin Gastroenterol, 2006, 20(6): 981-996.
8
Stinton LM, Myers RP, Shaffer EA. Epidemiology of gallstones [J]. Gastroenterol Clin North Am, 2010, 39(2): 157-169.
9
Cheng S, Zhang Y, Jiang L, et al. The association between inflammatory biomarkers and gallstones in Americans under 50 years old [J]. BMC Gastroenterol, 2025, 25(1): 393.
10
Zhang M, Mao M, Zhang C, et al. Blood lipid metabolism and the risk of gallstone disease: a multi-center study and meta-analysis [J]. Lipids Health Dis, 2022, 21(1): 26.
11
Soran H, Schofield JD, Durrington PN. Antioxidant properties of HDL [J]. Front Pharmacol, 2015, 6: 222.
12
Jiang Z, Jiang H, Zhu X, et al. The relationship between high-sensitivity C-reactive protein and gallstones: a cross-sectional analysis [J]. Front Med (Lausanne), 2024, 11: 1453129.
13
Rye KA, Barter PJ. Antiinflammatory actions of HDL: a new insight [J]. Arterioscler Thromb Vasc Biol, 2008, 28(11): 1890-1891.
14
Taborda NA, Blanquiceth Y, Urcuqui-Inchima S, et al. High-density lipoproteins decrease proinflammatory activity and modulate the innate immune response [J]. J Interferon Cytokine Res, 2019, 39(12): 760-770.
15
Niyonzima N, Samstad EO, Aune MH, et al. Reconstituted high-density lipoprotein attenuates cholesterol crystal-induced inflammatory responses by reducing complement Activation [J]. J Immunol, 2015, 195(1): 257-264.
16
Rosenson RS, Brewer HB Jr, Ansell BJ, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease [J]. Nat Rev Cardiol, 2016, 13(1): 48-60.
17
Warnatsch A, Ioannou M, Wang Q, et al. Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis [J]. Science, 2015, 349(6245): 316-320.
18
Liu Z, Fan Q, Wu S, et al. Compared with the monocyte to high-density lipoprotein ratio (MHR) and the neutrophil to lymphocyte ratio (NLR), the neutrophil to high-density lipoprotein ratio (NHR) is more valuable for assessing the inflammatory process in Parkinson's disease [J]. Lipids Health Dis, 2021, 20(1): 35.
19
Lai H, Tu Y, Zhang S, et al. Association of inflammation and abnormal lipid metabolism with risk of thrombosis and thrombosis progression in patients with polycythemia vera: a retrospective study [J]. Ann Hematol, 2023, 102(12): 3413-3426.
20
Chen T, Chen H, Xiao H, et al. Comparison of the value of neutrophil to high-density lipoprotein cholesterol ratio and lymphocyte to high-density lipoprotein cholesterol ratio for predicting metabolic syndrome among a population in the southern coast of China [J]. Diabetes Metab Syndr Obes, 2020, 13: 597-605.
21
Liu M, Liu X, Wei Z, et al. MHR and NHR but not LHR were associated with coronary artery disease in patients with chest pain with controlled LDL-C [J]. J Investig Med, 2022, 70(7): 1501-1507.
22
Liu X, Yan G, Xu B, et al. Association between monocyte-to-high-density lipoprotein-cholesterol ratio and gallstones in U.S. adults: findings from the National Health and Nutrition Examination Survey 2017-2020 [J]. Lipids Health Dis, 2024, 23(1): 173.
23
Ma D, Ma H, Li Y, et al. Association between Neutrophil-to-high-density lipoprotein-cholesterol ratio and gallstones: insights from the national health and nutrition examination survey (2017-2020) [J]. Lipids Health Dis, 2024, 23(1): 355.
24
Fu C, Chen J, Liu K, et al. Evaluating the link between high-density lipoprotein-related inflammatory indices and gallstone disease in U.S. adults [J]. Mediators Inflamm, 2026, 2026: 1925004.
25
Li H, Zhang C. Association between triglyceride-glucose index and gallstones: a cross-sectional study [J]. Sci Rep, 2024, 14(1): 17778.
26
Meng C, Liu K. Higher levels of systemic immune-inflammatory index are associated with the prevalence of gallstones in people under 50 years of age in the United States: a cross-sectional analysis based on NHANES [J]. Front Med (Lausanne), 2023, 10: 1320735.
27
Cho SK, Jung S, Lee KJ, et al. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio can predict the severity of gallstone pancreatitis [J]. BMC Gastroenterol, 2018, 18(1): 18.
28
Wang Y, Shang X, Zhang Y, et al. The association between neutrophil to high-density lipoprotein cholesterol ratio and gallstones: a cross-sectional study [J]. BMC Public Health, 2025, 25(1): 157.
29
Su Z, Gong Y, Liang Z. Prevalence of gallstone in Mainland China: A meta-analysis of cross-sectional studies [J]. Clin Res Hepatol Gastroenterol, 2020, 44(4): e69-e71.
30
Wang HH, Afdhal NH, Wang DQ. Estrogen receptor alpha, but not beta, plays a major role in 17beta-estradiol-induced murine cholesterol gallstones [J]. Gastroenterology, 2004, 127(1): 239-249.
31
Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease [J]. JAMA, 2005, 293(3): 330-339.
32
Shengelia M, Intskirveli N, Gogebashvili N. Inflammatory markers of gallstones disease in menopausal women [J]. Georgian Med News, 2012, (208-209): 52-55.
33
Maurer KJ, Rao VP, Ge Z, et al. T-cell function is critical for murine cholesterol gallstone formation [J]. Gastroenterology, 2007, 133(4): 1304-1315.
34
Muñoz LE, Boeltz S, Bilyy R, et al. Neutrophil extracellular traps initiate gallstone formation [J]. Immunity, 2019, 51(3): 443-450.e4.
35
Ouyang FW, Chiang HH, Hsu WL, et al. Dysfunctional high-density lipoprotein: an updated review [J]. Front Cardiovasc Med, 2025, 12: 1713387.
36
Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy [J]. N Engl J Med, 2011, 365(24): 2255-2267.
37
Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events [J]. N Engl J Med, 2014, 371(25): 2383-2393.
[1] 张宗明, 刘立民, 何小东, 陈孝平. 中国胆道外科发展历程、现状、挑战与未来展望[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(05): 681-691.
[2] 宋保华, 王斌, 帅青青, 张秀芝. 基于NHANES数据库的淋巴细胞-高密度脂蛋白胆固醇比值和代谢功能障碍相关脂肪性肝病的关系和阈值效应研究[J/OL]. 中华肥胖与代谢病电子杂志, 2026, 12(01): 1-8.
阅读次数
全文


摘要


AI
小
编
AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?